Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 4/2018

31.07.2018 | Brief Communication

Association of ki67 Index with Recurrence in Gastrointestinal Stromal Tumors

verfasst von: Patricia Segales-Rojas, Leonardo S. Lino-Silva, Eduardo Aguilar-Cruz, Rosa A. Salcedo-Hernández

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Gastrointestinal stromal tumors (GIST) have the potential to recur and metastasize. Several prognostic schemes have been developed but none are precise enough and most times the pathologist faces a small biopsy where it is not possible to evaluate the mitotic count. Our aim was to determine the influence of ki67 index and other clinicopathologic characteristics in the recurrence of GIST.

Methods

Forty-three consecutive cases of GIST were studied. The cases presented with non-metastatic disease. We compared the clinicopathologic features of cases with recurrence against those with non-recurrence. The ki67 index was determined by square-millimeters.

Results

The median age was 55 years (IQR 45–63), the most frequent site of involvement was the stomach with 21 (48.8%) cases, and the median of tumor diameter was 10 cm (IQR 5.5–17.5). Twenty-six (60.5%) cases were spindle cell, 13 (30.2%) were mixed, and 4 (9.3%) were epithelioid. The median mitosis count for 50 high power fields was 4 (IQR 0–16), while per square millimeter it was 1 (IQR 0–5, range 0–32). The median of the ki67 proliferation index was 5% (IQR 1–20). During the period of study, 11 (25.6%) patients recurred. The only significant differences between patients with GIST with recurrence and without recurrence were the sex and tumor size.

Conclusion

We did not find an association of the ki67 index with recurrence. The factors associated with recurrence were a high tumor size (> 10 cm) and male sex.
Literatur
1.
Zurück zum Zitat Kjetil S, Sandvick O, Soreide J, Giljaca V. Global epidemology of gastrointestinal stromal tumours (GIST): a systematic review of population based cohort studies. Cancer Epidemiol. 2016;40:39–56.CrossRef Kjetil S, Sandvick O, Soreide J, Giljaca V. Global epidemology of gastrointestinal stromal tumours (GIST): a systematic review of population based cohort studies. Cancer Epidemiol. 2016;40:39–56.CrossRef
2.
Zurück zum Zitat Das neves O, Oshima C, Artigiani-neto R, Yanaguibashi G, Lourenço L. Forones N. Ki67 and p53 in gastrointestinal stromal tumors – GIST. Arq Gastroenterol. 2009;46:116–20.CrossRef Das neves O, Oshima C, Artigiani-neto R, Yanaguibashi G, Lourenço L. Forones N. Ki67 and p53 in gastrointestinal stromal tumors – GIST. Arq Gastroenterol. 2009;46:116–20.CrossRef
3.
Zurück zum Zitat Zhao W-Y, Xu J, Wang M, Zhang ZZ, Tu L, Wang CJ, et al. Prognostic value of Ki67 index in gastrointestinal stromal tumors. Int J Clin Exp Pathol. 2014;7(5):2298–304.PubMedPubMedCentral Zhao W-Y, Xu J, Wang M, Zhang ZZ, Tu L, Wang CJ, et al. Prognostic value of Ki67 index in gastrointestinal stromal tumors. Int J Clin Exp Pathol. 2014;7(5):2298–304.PubMedPubMedCentral
4.
Zurück zum Zitat Seidal and Edvardsson. Expression of c-kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumours. Histopathology. 1999;34(5):416–24.CrossRef Seidal and Edvardsson. Expression of c-kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumours. Histopathology. 1999;34(5):416–24.CrossRef
5.
Zurück zum Zitat Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459–65.CrossRef Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459–65.CrossRef
6.
Zurück zum Zitat Cerski MR, Pereira F, Matte US, Oliveira FH, Crusius FL, Waengertner LE, et al. Exon 11 mutations, Ki67, and p16(INK4A) as predictors of prognosis in patients with GIST. Pathol Res Pract. 2011;207:701–6.CrossRef Cerski MR, Pereira F, Matte US, Oliveira FH, Crusius FL, Waengertner LE, et al. Exon 11 mutations, Ki67, and p16(INK4A) as predictors of prognosis in patients with GIST. Pathol Res Pract. 2011;207:701–6.CrossRef
7.
Zurück zum Zitat Di Vizio D, Demichelis F, Simonetti S, Pettinato G, Terracciano L, Tornillo L, et al. Skp2 expression is associated with high risk and elevated Ki67 expression in gastrointestinal stromal tumours. BMC Cancer. 2008;8:134.CrossRef Di Vizio D, Demichelis F, Simonetti S, Pettinato G, Terracciano L, Tornillo L, et al. Skp2 expression is associated with high risk and elevated Ki67 expression in gastrointestinal stromal tumours. BMC Cancer. 2008;8:134.CrossRef
8.
Zurück zum Zitat Toquet C, Le Neel JC, Guillou L. Elevated (>or=10%) MIB-1 proliferative index correlates with poor outcome in gastric stromal tumours patients: a study of 35 cases. Dig Dis Sci. 2002;47:2247–53.CrossRef Toquet C, Le Neel JC, Guillou L. Elevated (>or=10%) MIB-1 proliferative index correlates with poor outcome in gastric stromal tumours patients: a study of 35 cases. Dig Dis Sci. 2002;47:2247–53.CrossRef
9.
Zurück zum Zitat Meara RS, Cangiarella J, Simsir A, Horton D, Eltoum I, Chhieng DC. Prediction of aggressiveness of gastrointestinal stroma tumors based on immunostaining with bcl-2. Ki67 and p53. Cytopathology. 2007;18:283–9.CrossRef Meara RS, Cangiarella J, Simsir A, Horton D, Eltoum I, Chhieng DC. Prediction of aggressiveness of gastrointestinal stroma tumors based on immunostaining with bcl-2. Ki67 and p53. Cytopathology. 2007;18:283–9.CrossRef
10.
Zurück zum Zitat Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol. 1999;30:1213–20.CrossRef Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol. 1999;30:1213–20.CrossRef
11.
Zurück zum Zitat Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J. Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases. Am J Surg Pathol. 2000;24:1339–52.CrossRef Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J. Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases. Am J Surg Pathol. 2000;24:1339–52.CrossRef
12.
Zurück zum Zitat Kramer K, Knippschild U, Mayer B, Bögelspacher K, Spatz H, Henne-Bruns D, et al. Impact of age and gender on tumor related prognosis in gastrointestinal stromal tumors (GIST). BMC Cancer. 2015;15:57.CrossRef Kramer K, Knippschild U, Mayer B, Bögelspacher K, Spatz H, Henne-Bruns D, et al. Impact of age and gender on tumor related prognosis in gastrointestinal stromal tumors (GIST). BMC Cancer. 2015;15:57.CrossRef
Metadaten
Titel
Association of ki67 Index with Recurrence in Gastrointestinal Stromal Tumors
verfasst von
Patricia Segales-Rojas
Leonardo S. Lino-Silva
Eduardo Aguilar-Cruz
Rosa A. Salcedo-Hernández
Publikationsdatum
31.07.2018
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 4/2018
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-018-0150-z

Weitere Artikel der Ausgabe 4/2018

Journal of Gastrointestinal Cancer 4/2018 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.